OrthoPediatrics (KIDS)
(Delayed Data from NSDQ)
$31.95 USD
+0.73 (2.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $31.96 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.95 USD
+0.73 (2.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $31.96 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Zacks News
Wall Street Analysts Predict a 31.2% Upside in OrthoPediatrics (KIDS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 31.2% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 25.81% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 1.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 17.24% and 0.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?
by Zacks Equity Research
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 28.57% and 7.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.86% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (LFWD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ReWalk (LFWD) delivered earnings and revenue surprises of 61.54% and 4.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
by Zacks Equity Research
OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.
Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?
by Zacks Equity Research
OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Orthofix (OFIX) Soars 6.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Orthofix (OFIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Compared to Estimates, OrthoPediatrics (KIDS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 1.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
OrthoPediatrics (KIDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics
by Zacks Equity Research
The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will OrthoPediatrics (KIDS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.